Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Pedro Eusse outlines the Communist Party of Venezuela’s position on the Maduro government and responds to statements made by ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The Senate Armed Services Committee’s version of the fiscal 2026 defense policy bill, expected to be released later today, will incorporate sweeping acquisition reforms drawn from a separate bill ...

The $16 billion in disaster aid covers crop losses due to natural disasters from 2023 and 2024. It's the largest chunk of the ...

Understand the Insolvency and Bankruptcy Code's provisions for minimum payments to operational and dissenting financial creditors, including key amendments and the ongoing Supreme Court deliberation ...

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

In a statement on the approval, GSK said that a lower threshold means that nearly 70% of COPD patients in the US who are inadequately controlled on inhaled triple therapy could be eligible for Nucala.